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ABSTRACT
Muscle strength is a key clinical parameter used to monitor the
progression of humanmuscular dystrophies, includingDuchenne and
Becker muscular dystrophies. Although Caenorhabditis elegans is
an established genetic model for studying the mechanisms and
treatments of muscular dystrophies, analogous strength-based
measurements in this disease model are lacking. Here, we describe
the first demonstration of the direct measurement of muscular
strength in dystrophin-deficient C. elegans mutants using a
micropillar-based force measurement system called NemaFlex. We
show that dys-1(eg33) mutants, but not dys-1(cx18) mutants, are
significantly weaker than their wild-type counterparts in early
adulthood, cannot thrash in liquid at wild-type rates, display
mitochondrial network fragmentation in the body wall muscles, and
have an abnormally high baseline mitochondrial respiration.
Furthermore, treatment with prednisone, the standard treatment for
muscular dystrophy in humans, andmelatonin both improvemuscular
strength, thrashing rate and mitochondrial network integrity in
dys-1(eg33), and prednisone treatment also returns baseline
respiration to normal levels. Thus, our results demonstrate that the
dys-1(eg33) strain is more clinically relevant than dys-1(cx18) for
muscular dystrophy studies inC. elegans. This finding, in combination
with the novel NemaFlex platform, can be used as an efficient
workflow for identifying candidate compounds that can improve
strength in the C. elegansmuscular dystrophy model. Our study also
lays the foundation for further probing of the mechanism of muscle
function loss in dystrophin-deficientC. elegans, leading to knowledge
translatable to human muscular dystrophy.
This article has an associated First Person interview with the first
author of the paper.
KEY WORDS: Muscular dystrophy, C. elegans, Muscle strength,
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INTRODUCTION
Duchenne muscular dystrophy (DMD) and Becker muscular
dystrophy (BMD) are muscular wasting disorders that affect both
skeletal and cardiac muscle and result from mutations in the
dystrophin gene (Le Rumeur, 2015). Dystrophin is a protein
encoded by the longest human gene, which is over 2.3 million base
pairs long and has complex interactions with muscle contraction and
muscle cell membrane stability (Den Dunnen et al., 1989; Blake
et al., 2002). DMD results from null mutations in the gene, while
BMD, a less severe form of the disorder, is typically caused by a
mutation resulting in a partially functional dystrophin protein (Le
Rumeur, 2015). The prevalence of these diseases is more than 1 in
4000 male births, expressing as an X-linked disorder. Prognosis is
poor (Moser, 1984), and the only standard approved treatment in the
USA for symptoms of DMD is the corticosteroid prednisone, which
typically has the effect of extending ambulation by a couple of years
(DeSilva et al., 1987). Although the increase in ambulatory period is
a favorable outcome of treatment, chronic prednisone use typically
results in a cushingoid appearance and other unfavorable side
effects (Mendell et al., 1989; Malik et al., 2012). Thus, the
prognosis and options for DMD/BMD treatment are rather limited.
To monitor progression of the disease or to test for efficacy of
treatments, various diagnostic tools have been studied to monitor
the deterioration of muscle in DMD patients. One diagnostic tool
used is an electronic strain gauge that measures isometric muscle
strength; this tool can discern DMD patients from the control in all
muscle groups tested, with the most drastic differences occurring in
the knee extensors, where DMD patients have less than a tenth of the
strength of the control group (Brussock et al., 1992). Quantitative
muscle testing (QMT), a method that is more sensitive to small
changes in muscle strength, is also being implemented in young
patients with DMD to monitor muscle strength across age. QMT is
able to detect isometric and isokinetic losses in strength before the
end of the first decade of life (Lerario et al., 2012). These are just
two examples of a larger research effort to obtain more reliable
measures of muscle strength, as muscle strength is regarded as a key
clinical parameter of interest in tracking DMD disease progression.
Over the past half century, research efforts surrounding muscular
dystrophy have grown significantly, but we still have much to learn
about this debilitating disease.
Although there have been extensive research efforts to better
understand the mechanisms of and treatments for muscular
dystrophy in vertebrate model organisms such as rodents and
canines, these systems are limited in their throughput, can be cost
prohibitive and also have some ethical issues (McGreevy et al.,Received 19 June 2018; Accepted 30 October 2018
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2015). This has led researchers to utilize Caenorhabditis elegans to
study muscular dystrophy over the past couple of decades (Ségalat,
2006; Chamberlain and Benian, 2000). C. elegans is a premier
model organism for studying a number of biological processes and
human diseases, with an estimated 40% of human disease genes
having an ortholog in C. elegans (Culetto and Sattelle, 2000).
The ability to translate results from C. elegans to humans comes, in
part, from conserved major biological pathways between the two
organisms and a fully sequenced nematode genome (The C. elegans
Sequencing Consortium, 1998). C. elegans also has musculature
strikingly similar to that of humans, with the presence of dense
bodies (analogous to z-disks) and m-lines (Gieseler et al., 2016). A
number of muscle proteins in C. elegans resemble human proteins
in their function, makingC. elegans an excellent model for studying
muscle ailments such as sarcopenia or muscular dystrophy (Ségalat,
2002). In addition to these factors, C. elegans also has a short
lifespan of only 3 weeks, produces a new generation every 3.5 days
and is lowmaintenance, with cultures grown on agar medium and an
Escherichia coli diet.
Several mutant strains of C. elegans have been generated for
investigating the mechanistic details of and pharmacological
treatments for dystrophin deficiency. About two decades ago,
Bessou et al. reported a gene in C. elegans that they called dys-1
(Bessou et al., 1998). dys-1 encodes a protein resembling the human
dystrophin protein not properly transcribed in DMD and BMD.
These C. elegans dys-1 mutants are hyperactive, have exaggerated
head bending, hypercontract their bodies during backwards
movements and are hypersensitive to the acetylcholinesterase
inhibitor aldicarb. However, the animals do not show visible
defects in their musculature, which the authors attribute to the short
timescale of the nematode’s life (Bessou et al., 1998). To address the
need for a health measure related directly to the musculature in dys-1
mutants, Gieseler et al. generated a sensitized dys-1 mutant
containing an additional mutation in the hlh-1 gene, which is a
homolog for the mammalian MyoD (also known as Myod1) gene
(Gieseler et al., 2000). The presence of the hlh-1mutation in a dys-1
mutant background results in significant muscle cell degeneration
that is not present in mutants with either the hlh-1 or dys-1mutation
alone (Gieseler et al., 2000). This type of double mutation was
modeled after a similarMyoD mutation studied in conjunction with
the mdx mouse model, which was generated, in part, to create a
system that recapitulated the pathophysiology of DMD in humans
(Megeney et al., 1996). Using this dys-1; hlh-1 model of muscular
dystrophy, pharmacological compounds like prednisone and
serotonin have been shown to be effective in reducing muscle cell
degeneration. These two treatments came as hits out of large-scale
screens, from which hundreds of other compounds were deemed
ineffective (Gaud et al., 2004; Carre-Pierrat et al., 2006).
Although these studies have helped to establish C. elegans as a
model organism for muscular dystrophy and pharmacological
treatments for the disease, two main criticisms arise. First, it is
unknown whether results from the dys-1; hlh-1 double mutant
models can be translated to muscular dystrophy in humans,
especially given that the mechanism of these enhanced muscular
degeneration effects in C. elegans is not fully understood. Second,
although several assays for assessing health of dys-1 mutants have
been proposed, most fail to directly score animals for muscle
function and instead look at indirect physiological parameters, such
a locomotion speed, or subcellular markers, such as muscle cell
damage. Beron et al. scored the percentage of worms that can travel
a set distance in a certain amount of time when placed in a 3D
burrowing environment (Beron et al., 2015). Animals were
stimulated by chemotaxis to burrow down the length of a plastic
pipette filled with agar, and dys-1(cx18) and dys-1(eg33) were both
highly deficient in burrowing ability compared with the wild-type
control. This work indicates that the dys-1 mutants might be unable
to burrow correctly due to defects in muscular strength.
Although these assays are undoubtedly valuable, the ability to
directly evaluate muscle function would offer a more meaningful
dimension for assessing the health of dystrophin mutants under
treatments, given that strength is a clinical measure used to assess
progression of DMD in humans. Previously our group established a
novel technique and workflow for reliably measuring the muscle
strength ofC. elegans, independent of their behavior. This platform,
NemaFlex, consists of a microfluidic device containing deformable
pillars that the worm deflects as it crawls in the chamber. Nematode
strength is scored from the maximal pillar deflections via a
sophisticated image-processing software (Rahman et al., 2018). To
establish strength as a phenotype of interest for assessing health in
dys-1 mutants, we used NemaFlex for studying two different dys-1
strains, dys-1(cx18) and dys-1(eg33), alongside the wild-type
animal. We show that our platform can detect pharmacologically
induced improvements by assessing the effects that melatonin and
prednisone, compounds known to improve muscle health, have on
the muscular strength of the same animals. We also evaluated
whether the thrashing data and mitochondrial integrity for control
and treatment groups agreed with the strength data. Finally, we show
that mitochondrial network integrity and mitochondrial function are
impaired in dys-1(eg33), and treatment with prednisone repairs
these defects. This work addresses the current gap in the ability to
obtain strength measures in DMD model mutants, which will
ultimately lead to a better understanding of muscular dystrophy.
Additionally, our results indicate that dys-1(eg33) has a more
pronounced and clinically relevant phenotype than what has been
reported previously for dys-1 mutants. We can detect our clinically
relevant phenotype in the absence of the hlh-1 sensitizing mutation,
which better establishes C. elegans dys-1mutants as a useful model
for studying muscular dystrophy.
RESULTS
dys-1(eg33), but not dys-1(cx18), worms are weaker than
wild type
Although both dys-1 mutants have previously been shown to have
declined locomotory capability and decreased lifespan compared
with the wild-type animal (Oh and Kim, 2013), direct measures of
muscle functionality in clinically relevant models do not exist. We
addressed this limitation by utilizing our microfluidic platform
called NemaFlex that enables measurement of the muscular strength
of C. elegans (Rahman et al., 2018). Using two previously studied
dystrophin-deficient mutants, dys-1(eg33) and dys-1(cx18), we
investigated whether these animals were weaker than the wild-type
animal (N2). The alleles eg33 and cx18 are nonsense mutations
predicted to encode truncated forms of DYS-1 at amino acid (AA)
3287 and AA 2721, respectively (Oh and Kim, 2013). Animal
strength of wild type, dys-1(cx18) and dys-1(eg33)was measured on
Days 1, 3 and 5 of adulthood (Fig. 1A). Although neither mutant
strength value was significantly different from that of wild type on
the first day of adulthood, dys-1(eg33) animal strength essentially
plateaued, whereas wild type and dys-1(cx18) continued to grow
stronger at the later time points, which was potentially partially
attributable to the increase in animal diameter in early adulthood.
This led to dys-1(eg33) being significantly weaker than the
wild-type control on Days 3 and 5, thus establishing the
dys-1(eg33) strain as a model exhibiting muscular weakness with
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age, which is similar to the phenotype displayed in muscular
dystrophy. It is important to note that animal diameter, but not
length, strongly affects the muscle strength of C. elegans, as we
previously reported that strength tends to increase with body
diameter (Rahman et al., 2018). Therefore, we checked whether
muscle strength deficiencies in dys-1(eg33) were attributable to
differences in their diameters compared with wild-type animals
(Fig. 1B). At no time point are dys-1(eg33) animals significantly
thinner than wild type, thus indicating that their strength defect is
not a size-based effect, and that we are truly measuring strength
deficiencies resulting from defects in muscle function.
All treatments improve dys-1(eg33) strength, some
to wild-type levels
Because NemaFlex can detect muscular weakness in dys-1(eg33), a
meaningful next step is to test whether compounds known to
improve muscle health can also improve muscle strength in
muscular dystrophy models. Melatonin and prednisone were
selected for validation of NemaFlex as a platform for screening
compounds for treatment of dystrophin deficiency in C. elegans.
Melatonin is thought to be potentially useful in treating muscle
degradation with age (Coto-Montes et al., 2016) and has also been
used to treat muscular dystrophy patients (Chahbouni et al.,
2010). Prednisone is the standard treatment for muscular
dystrophy patients (Malik et al., 2012) and has also been
shown to decrease the number of abnormal muscle cells in the
dys-1; hlh-1 double mutant strain of C. elegans (Gaud et al.,
2004). The mechanism behind prednisone’s improvement in
muscle function is still up for debate, but the efficacy of
prednisone previously shown in C. elegans provides evidence
that corticosteroids treat the muscle in ways other than reducing
inflammation, given that C. elegans does not have an
inflammatory pathway (Gaud et al., 2004).
In general, we find that wild-type and dys-1(cx18) animals treated
during development and continuing through adulthood were not
significantly different from their control counterparts at all three
time points (Fig. 2A,B). In contrast, beginning on Day 3 of
adulthood, when dys-1(eg33) animals are significantly weaker than
wild type, all four treatments improve muscular strength compared
with the untreated dys-1(eg33) animals (Fig. 2C). Moreover, it is
important to note that worm diameters are minimally affected under
treatments for wild type (Fig. 2D), dys-1(cx18) (Fig. 2E) and
dys-1(eg33) (Fig. 2F). Of particular importance is that on Days 3
and 5, when dys-1(eg33) has significant improvements in muscle
strength, there are no changes in worm diameter under any treatment
condition. Thus, improvements in animal strength are not due to
changes in animal size, but rather due to improvements in muscle
function. Under some treatments, differences between the wild-type
control and treated dys-1(eg33) are indiscernible. Several treatments
improve animal strength by over 50% and get within 10% of the
wild-type control strength value. As anticipated, these treatments
improve muscle functionality in the muscular dystrophy model in a
manner that can be detected by NemaFlex. This establishes our
technology as a useful platform for future studies screening novel
compounds on dys-1(eg33) to select potential therapies for
muscular dystrophy. Because dys-1(eg33) is showing such a
distinct phenotype from dys-1(cx18), which has been studied
more thoroughly, we were interested in investigating the difference
between these two strains and why dys-1(eg33) seems to have more
clinical relevancy.
Functional defects are apparent in swimming-based
movement assays
A standard assay for detecting locomotion defects is to record a
worm’s thrashing frequency when placed in a liquid environment,
and this assay has been used previously to look at dystrophin-
deficient worms, although not in both the dys-1 strains we used in
this study (Hueston and Suprenant, 2009). We were curious to
compare the outputs of an indirect measure of muscle function,
thrashing, with our more direct measure, the strength measurement.
Interestingly, although the muscle strength of dys-1(cx18) was not
significantly less than that of the wild-type animal, its thrashing rate
was significantly less than that of wild type. dys-1(eg33) also
showed a thrashing rate lower than that of both wild type and
Fig. 1. Strength measurements of muscular dystrophy model mutants. (A) Baseline strength of the three different strains taken at three different time points.
Measurements began in early adulthood once animals had been transferred to the microfluidic devices. Error bars represent s.e.m. dys-1(eg33), but not
dys-1(cx18), is detectably weaker than the wild-type (WT) animal. This effect of dystrophin loss on animal strength is detected beginning on Day 3.
(B) The differences in animal strength are not attributable to their diameters, as dys-1(eg33) animals areweaker, but not thinner, than theWTanimals. [N for Day 1,
3, 5: WT, N=27, 23, 22; dys-1(cx18), N=29, 24, 22; dys-1(eg33), N=28, 21, 18. Single replicate analyzed with a two-sample t-test.] ****P<0.0001; n.s.,
nonsignificant.
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dys-1(cx18), consistent with its lower strength (Fig. 3A). When all
strains were treated with life-long melatonin or prednisone, there
were some noticeable changes in the thrashing rate, although not the
same as the changes in muscle strength in all cases. Wild-type
animals had varying responses to the drugs, with the drugs not
having a consistent effect on the worms across the time points
studied (Fig. 3B,C). However, both treatments give a minor
improvement in dys-1(cx18) (Fig. 3C), and they both offer a
significant improvement in thrashing rate at all time points in
dys-1(eg33) (Fig. 3D). This result matches well with the strength
data, where all drug treatments improve muscle strength in
dys-1(eg33). The thrashing assay thus helps to further implement
dys-1(eg33) as a more clinically relevant model, where measures
from two unique modes of locomotion show improvement when
animals are treated with compounds known to improve muscle
health, particularly in patients with muscular dystrophy.
Fig. 2. Effect of pharmacological interventions on nematode strength. (A-F) The strengths for three different strains, each with a control and four treatments,
are shown. Each strain was treated with melatonin and prednisone during development alone (M1, P1) or during development and adulthood (M2, P2);
‘C’ designates the control animals, which received no treatment. With the exception of wild-type animals undergoing development-only prednisone treatment,
the wild type (A) and dys-1(cx18) (B) have no changes in strength in response to treatment. In contrast, all dys-1(eg33) animals improve their strength under any
of the four treatments beginning on Day 3 (C). Worm diameters do not fluctuate much for wild type (D), dys-1(cx18) (E) or dys-1(eg33) (F) under the various
treatments. In the case of dys-1(eg33), the diameter is not influenced at all by any treatments on Days 3 and 5, the time points at which strength improves
drastically under treatment. These data indicate that strength improvements are not due to changes in animal size. Error bars represent s.e.m. [N for Day 1, 3, 5.
WT: M1, N=27, 26, 25; M2, N=26, 25, 26; P1, N=26, 24, 23; P2, N=27, 24, 22. dys-1(cx18): M1, N=29, 27, 25; M2, N=30, 24, 24; P1, N=28, 28, 21;
P2, N=28, 28, 26. dys-1(eg33): M1, N=27, 25, 23; M2, N=29, 25, 25; P1, N=29, 26, 23; P2, N=27, 25, 26. Single replicate analyzed with a two-sample t-test.]
*P<0.05, **P<0.01, ***P<0.001; n.s., nonsignificant.
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dys-1(eg33)mutants have a more severe phenotype than
dys-1(cx18)
Given that strength and thrashing ability are not compromised to the
same extent in dys-1(cx18) as in dys-1(eg33), we wanted to further
investigate the differences between the two strains. Upon reviewing
the published literature on dys-1(cx18), we found that Hueston and
Suprenant (2009) had previously observedworse locomotion at 25°C
than at 20°C, which would be consistent with cx18 being a
temperature-sensitive allele. We confirmed that dys-1(cx18), but not
dys-1(eg33), displays temperature sensitivity in the extent of
thrashing ability (Fig. 4A). We next examined whether differences
between dys-1(cx18) and dys-1(eg33) extended to differences in
excitation-contraction coupling. Both dys-1(cx18) and dys-1(eg33)
display resistance to levamisole-induced paralysis, indicative of
defects in postsynaptic excitation-contraction coupling, with
dys-1(eg33) displaying more pronounced levamisole resistance
(Fig. 4B). Similar to the thrashing ability, dys-1(cx18) displayed
temperature sensitivity to the effects of levamisole (Fig. 4C). These
results confirm the past observation that dys-1(cx18) is a temperature-
sensitive allele of dys-1 and confirm that muscle responsiveness to a
depolarizing signal is more compromised in dys-1(eg33).
Dystrophin mutants display normal sarcomere structure
We visualized the sarcomere structure of dys-1(cx18) and
dys-1(eg33) worms to determine whether defects in muscle
structure account for the reduced strength and motility in the dys-1
worms. Similar to previous studies (Gieseler et al., 2000), we also
detect nomajor differences in sarcomere structure in the dys-1(eg33)
and dys-1(cx18) compared with wild-type worms, by either
phalloidin staining (Fig. 5A) or visualization of myosin-tagged
GFP (Fig. 5B). These findings suggest that the reductions in strength
are not attributed to changes in muscle architecture in the dys-1
strains and are perhaps a result of different mechanism(s).
Mitochondrial fragmentation is a phenotype of dystrophin
mutants
To determine the possible underlying mechanisms behind the loss
of muscle strength in dystrophin mutants, we looked at the integrity
of the mitochondrial network of dys-1(cx18) and dys-1(eg33)
animals that had been crossed with the CB5600 strain, which
expresses GFP in the mitochondria and nuclei of the body wall
muscles. Recently, Scholtes et al. (2018) reported mitochondrial
fragmentation as a phenotype of their sensitized muscular dystrophy
Fig. 3. Swimming dystrophin mutants have lower thrashing rates than wild type, and both dys-1(cx18) and dys-1(eg33) respond positively to
treatments. (A) Both dys-1(cx18) and dys-1(eg33) have lower thrashing rates than wild type (WT) across all ages. (B) WT, (C) dys-1(cx18) and (D) dys-1(eg33)
have varying responses to drug treatments. The most prominent response is that of dys-1(eg33), which improves its thrashing rate drastically under both
treatments at all time points. C, control; M,melatonin across life (similar to previousM2 condition); P, prednisone across life (similar to previous P2 condition). Error
bars represent s.e.m. For all strains and treatments at each time point, N=10, with five replicates for each worm, with three independent biological replicates for a
total of 150 data points per bar; results were analyzed with a two-sample t-test. *P<0.05, ****P<0.0001; n.s., nonsignificant.
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strain, dys-1; hlh-1. Here, we report that mitochondrial network
integrity is also compromised in dys-1(cx18) and dys-1(eg33)
compared with wild-type animals of the same age, with the defect in
dys-1(eg33) being more severe (Fig. 5C-E). Both prednisone and
melatonin improve the mitochondrial integrity of dys-1(eg33)
animals. This offers a potential mechanistic explanation for why
muscle function appears to be more severely affected in dys-1(eg33)
than in dys-1(cx18), as well as further evidence that prednisone and
melatonin are directly improving muscle health in dys-1(eg33).
Mitochondrial function is affected in dys-1(eg33)mutants
Having identified that mitochondrial network structure appears
disrupted in dys-1 mutants and that this is improved with
prednisone treatment, we were curious whether mitochondrial
function was similarly affected. We first used mitochondrial dyes to
assess mitochondrial membrane potential. JC-10 is a dye that collects
in the mitochondria based on membrane potential and exits as the
mitochondrial membrane potential changes over time, as previously
shown in anotherC. elegansmutant (Gaffney et al., 2015). Compared
with wild-type animals, dys-1(cx18) has a somewhat reduced
mitochondrial membrane potential, while dys-1(eg33) is more
severely affected (Fig. 6A). To confirm these defects in
mitochondrial membrane potential, we used a second dye,
MitoTracker Red, which collects in the mitochondria based upon
membrane potential, but, unlike JC-10, does not exit themitochondria
once inside (Gaffney et al., 2014). The MitoTracker Red
accumulation matched that of JC-10 (Fig. 6A), demonstrating that
the impairedmembrane potential in the JC-10-dyedwormswas not an
artifact of loss of membrane potential during the staining procedure.
Interestingly, with both dyes, prednisone does not improve the defect
in membrane potential in dys-1(eg33), indicating that improvements
that we see in strength and thrashing rate in dys-1(eg33) under
prednisone treatment can be attributed to a different mechanism.
In order to quantify the defect in mitochondrial function in
dys-1(eg33)mutants, we assessed oxygen consumption rates (OCRs).
Although dys-1(cx18) have normal OCR compared with wild type,
dys-1(eg33) have abnormally high baseline respiration (Fig. 6B).
Treatment with the uncoupling agent carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP) revealed that unlike
wild type and dys-1(cx18), dys-1(eg33) had no statistically
significantly detectable, spare respiratory capacity (Fig. 6B).
No statistically significant differences in non-mitochondrial
respiration, as assessed by treatment with sodium azide, were found
between the strains. Thus, the lack of spare respiratory capacity in
dys-1(eg33) is likely a key driver of the increased severity of muscle
defects in dys-1(eg33) versus dys-1(cx18).
Given that prednisone treatment improves muscle strength,
thrashing rate and mitochondrial network integrity in dys-1(eg33),
we were interested in determining whether prednisone could also
normalize the aberrantly high basal OCR. Indeed, treating dys-1(eg33)
with prednisone returned basal OCR to wild-type levels (Fig. 6C).
These results, combined with the lack of major effect of prednisone on
mitochondrial membrane potential (Fig. 6A), suggest that prednisone
has a predominant effect on mitochondrial respiratory function rather
than restoringmembrane potential. This is interesting, as Brouilly et al.
(2015) recently showed that prednisone improves muscle membrane
structure, including the mitochondria, in dys-1; hlh-1.
DISCUSSION
Strength as a novel phenotype for C. elegans DMD studies
In the present study, we demonstrate the ability tomeasure the strength
of C. elegans dys-1 mutants and detect functional improvements in
Fig. 4. dys-1(cx18) shows a temperature-sensitive phenotype, and
dys-1(cx18) and dys-1(eg33) are levamisole resistant. (A) Day 1 adult
dys-1(cx18) animals have lower thrashing rates when cultured at 25°C than
at 20°C, whereas dys-1(eg33) is not affected by higher culture temperatures.
Thus, dys-1(cx18) appears to be temperature sensitive. For all strains and
treatments at each time point, N=10 with five replicates for each worm, with
three independent biological replicates for a total of 150 data points per bar.
Significances were analyzed using a two-way ANOVA with Tukey’s multiple
comparison test. (B,C) dys-1(cx18) has amild levamisole resistance compared
with wild type (WT), while dys-1(eg33) has a high resistance, both at 20°C and
25°C. At 20°C, n=50 for two independent biological replicates (total n=100
per strain); at 25°C, n=50 per strain. **P<0.01, ***P<0.001 and ****P<0.0001,
for response to levamisole versus other strains tested. Two-way repeated
measures ANOVA was used for statistical analysis.
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muscle strength in dys-1(eg33) after treatment with compounds
known to improvemuscle health. Previously, therewas not a means to
directly measure the strength of C. elegans, but recently our group
established a consistent and reliable strength measurement routine
using our microfluidic NemaFlex device (Rahman et al., 2018). This
has allowed us to demonstrate, for the first time, that strength
deficiency is a phenotype of the dys-1(eg33) strain, which further
represents C. elegans as a useful model for replicating some of the
pathophysiologies of human diseases in nematodes.
For high-throughput drug screens with dystrophin-deficient
C. elegans, it might not be feasible to measure a large quantity of
parameters to quantify nematode health. We show here that the
thrash assay detects deficiencies in both dys-1 mutants and
improvements under treatment with compounds. However, a
decrease in thrashing rate does not necessarily correlate with a
loss of muscle strength. For example, wild-type animals have lower
thrashing rates on Days 3 and 5 than on Day 1, although there is not
a strength decline at this same time point. Therefore, thrashing rate
and muscle strength measures do not necessarily report on the same
aspect of worm physiology. For the purpose of high-throughput
drug screens, an automated version of the thrashing assay would be
a quicker way of determining hits (Buckingham et al., 2014); we
propose that our NemaFlex system would be useful in validating
whether these drugs also improve the more clinically relevant
measure of muscle strength. Further automation of our NemaFlex
imaging and postimaging analysis protocol could help make
NemaFlex more reasonable as a first-step screening assay;
however, under the current protocol, throughput is somewhat
limited and would thus be more appropriate as an assay to validate
hits that come out of a thrashing-based drug screen or other
high-throughput screening method.
Therefore, we propose that a direct measure of muscle function is
perhaps the most valuable single measure to extract from drug
screens. We recognize the value in assessing other physiological
abilities, as dys-1(eg33) animals are also deficient in thrashing and
burrowing. Advantages of our system over the previously reported
burrowing assay (Beron et al., 2015) include the ability to culture
the nematode over its whole life while maintaining individual worm
identity and controlling the contents of the fluidic environment in a
temporal manner. There is also no requirement of a stimulus for
observation of the desired phenotype, which is easy to observe due
to the transparency of the platform, which allows for clear imaging
Previous studies with dystrophin-deficient C. elegans have also
looked at non-physiological measures that aim to assess the integrity
of the muscle rather than the function. If muscle strength is
improved under a certain drug treatment, previously described
assays looking at non-physiological measures should then be used
to further assess the efficacy of the treatment. Our transgenic dys-1
strains expressing GFP in mitochondria of the body wall muscle that
we report here are perfectly suited for this purpose, although other
methods have previously been reported as well. Beron et al. (2015)
looked at muscle degeneration in burrowing animals by tagging
muscle cell nuclei and mitochondria with GFP, and others have
looked at body wall muscle integrity after staining (Gieseler et al.,
2000; Mariol and Ségalat, 2001). Looking at muscle cell integrity
under a certain drug treatment could thus entail using the dys-1;
Fig. 5. There are no differences in sarcomere structure between dys-1 andwild-typeworms; however, mitochondrial network defects are apparent, and
pharmacological intervention prevents degradation from occurring. (A) Representative images of wild-type (WT), dys-1(cx18) and dys-1(eg33) worms
stained with phalloidin on Day 1 of adulthood. (B) Representative images of PJ727, CC97 [dys-1(cx18)] and CC96 [dys-1(eg33)] worms on Day 3 of adulthood.
Sarcomere defects are not apparent in either dys-1 mutant. Scale bar: 25 μm. (C) CB5600 (WT with GFP-tagged mitochondria) animals have a tubular
mitochondrial network appearance, which is also maintained in animals treated with prednisone and melatonin. (D) CC90 animals [GFP-tagged mitochondria
in dys-1(cx18)] exhibit minor fragmentation in the mitochondrial network, which is remedied by prednisone but not melatonin. (E) CC91 animals [GFP-tagged
mitochondria in dys-1(eg33)] have noticeably fragmented mitochondrial networks. Animals treated with prednisone do not display this phenotype and instead
have relativelyWT-like appearance in themitochondrial network. Animals treated with melatonin have slightly improvedmitochondrial network integrity but are not
improved to WT levels. Scale bar: 25 μm; the enlarged regions are an additional 1.7× magnification.
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hlh-1 mutant or allowing worms to burrow in the presence of the
drug of interest to hasten muscle damage in one of the single
mutation dys-1 strains.
Differences in muscle strength and other phenotypes
between dys-1(eg33) and dys-1(cx18)
The inability of NemaFlex to detect muscular defects in dys-1(cx18)
in a crawling environment is not surprising, given that adult worms
similarly aged to the ones studied here have no abnormal muscle
cells and are indiscernible from wild-type animals based on this
parameter (Gieseler et al., 2002). Additionally, the mitochondrial
fragmentation is not as severe in dys-1(cx18) as in dys-1(eg33).
However, the question still remains on what the key differences are
between dys-1(eg33) and dys-1(cx18) that lead to these drastic
differences in muscle functionality, especially given that both
animals are deficient in thrashing (our results here) and burrowing
(Beron et al., 2015). Crawling, swimming and burrowing are
kinematically distinct from one another and offer unique challenges
for the worm; observing different phenotypes among these
environments could result from this distinction. It is likely that the
burrowing assay challenges the muscles in a way not done in
NemaFlex. Burrowing relies on the head muscles, while the
NemaFlex analysis selects for the maximum force exertion,
typically coming from body wall muscles. Therefore, if head
muscles were weaker, our system would not detect this under the
current workflow. We also see that in the swimming worms, where
both dys-1(cx18) and dys-1(eg33) are slower thrashers, dys-1(cx18)
does not respond quite as strongly to the drug treatments.
Further assessment with these three unique functional readouts,
along with future efforts targeting mechanistic questions, could
help answer why dys-1(eg33) shows an impaired phenotype and
dys-1(cx18) does not. Previous work with C. elegans has identified
defects in calcium signaling and acetylcholine sensitivity as
pathophysiologies associated with dystrophin deficiency, so it is
possible that these defects are more severe in dys-1(eg33) than in
dys-1(cx18) (Mariol and Ségalat, 2001; Zhan et al., 2014; Bessou
et al., 1998; Giugia et al., 1999). However, both strains are also
reported as having null mutations, indicating that neither strain should
produce even a partially functional dystrophin product. It thus
remains unclear why the worms exhibit some distinct phenotypes
from one another, but our data reported in this paper support the
notion that there are fundamental differences between dys-1(eg33)
and dys-1(cx18). The more severe phenotype of dys-1(eg33) in its
levamisole resistance and basal OCR, as well as the temperature-
sensitive nature of dys-1(cx18), offer further perspective onwhy these
strains differ from one another in their physiologies.
Oh and Kim (2013) previously showed that dys-1(eg33) has higher
levels of GST-4 reporter than dys-1(cx18). Increased gst-4 expression
leads to increased resistance to oxidative stress (Leiers et al., 2003),
and this is entirely consistent with our OCR data for dys-1(eg33).
Additionally, we also showed that dys-1(cx18) display temperature
sensitivity in their thrashing movement. Similar movement data for
dys-1(cx18) were reported at 25°C (Hueston and Suprenant, 2009);
thus, our data are consistent with published data. The nonsense
mutation in dys-1(cx18) corresponds to termination at AA 2721,
which is immediately before the start of spectrin repeat domain 5,
Fig. 6. Mitochondrial dysfunction is also a
phenotype of dys-1(eg33). (A) JC-10- and
MitoTracker Red-stained mitochondria show moderate
depolarization of the mitochondrial membrane in
dys-1(cx18) and severe depolarization in dys-1(eg33).
This defect is not remedied by treatment with prednisone
in dys-1(eg33). Scale bar: 30 µm. (B) Compared with
wild type (WT) and dys-1(cx18), dys-1(eg33) has an
abnormally high basal oxygen consumption rate (OCR),
while maximal respiratory capacity is unaffected.
Significances were assessed using a one-way ANOVA
and Bonferroni multiple corrections. (C) Treatment with
prednisone restores basal OCR to WT levels in
dys-1(eg33) animals. Significance was assessed using
a one-way ANOVA with Tukey’s multiple comparison
test. All OCR data are based on 20 worms per well with
five wells per strain/condition. *P<0.05, **P<0.01; n.s.,
nonsignificant.
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which starts at AA 2725. The temperature-sensitive nature of the
movement decline in dys-1(cx18), but not dys-1(eg33), suggests that
dys-1(cx18) probably produces a partially functional protein in a
temperature-sensitive fashion. This idea of more unfolding occurring
at 25°C is consistent for other metastable temperature-sensitive
mutations in C. elegans (Ben-Zvi et al., 2009).
Prednisone and melatonin improve strength in C. elegans
The two pharmacological compounds that we test here, prednisone
and melatonin, offer improvements in muscle strength and may also
elucidate mechanisms behind muscle strength loss in muscular
dystrophy. Previously, Gaud et al. (2004) reported that prednisone
reduces the number of abnormal muscle cells in their dys-1; hlh-1
model. We demonstrate here that prednisone gives a functional
improvement in the dys-1(eg33) animal as well. Although
dys-1(eg33) does not exhibit major defects in the sarcomeres like
in the sensitized models, we can still detect and treat strength
declines. This is in contrast to our past work with integrin
attachment complex mutants, where both sarcomere and
mitochondrial defects were present in animals that were
detectably weaker (Etheridge et al., 2015). Our results here
indicate that NemaFlex can detect alterations in strength in the
absence of major structural defects in muscle, which raises the
question of whether mitochondrial deficits, rather than very minor
sarcomere deficits, underlie the detected loss of strength.
While we are able to detect functional improvements under both
drug treatments, the exact mechanism by which prednisone helps to
alleviate symptoms is not known, although efficacy is at least, in
part, attributed to reduction of inflammation (Parrillo and Fauci,
1979; Mendell et al., 1989). Another proposed mechanism is
protection against mechanically induced muscle damage (Jacobs
et al., 1996). Also, little is known about the mechanism of melatonin
in the treatment of dystrophin-deficient muscle, although it has been
demonstrated to reduce oxidative stress markers in erythrocytes in
blood samples from humans with DMD (Chahbouni et al., 2011). In
DMD patients treated with melatonin, several measures scoring
oxidation and inflammation were also improved over a 9-month
treatment period (Chahbouni et al., 2010). Functional measures
were not reported for this study, but mdx mice treated with
melatonin show decreased creatine kinase levels and improved
muscle function in another study (Hibaoui et al., 2011). These
proposed mechanisms could be studied further using the C. elegans
DMD model that we present here.
dys-1(eg33) shows clinical relevancy
Given that dys-1(eg33) is weaker than the wild type and responds
well to prednisone treatment, the standard treatment for muscular
dystrophy in humans, we are convinced that this particular strain
could currently be the most clinically relevant model of C. elegans
for muscular dystrophy, especially when considering that much of
the muscular dystrophy work has been done with the genetically
sensitized strain, dys-1(cx18); hlh-1. Null mutations of hlh-1,
although not inhibitory to muscle development, do lead to muscle
that contracts poorly and animals that are uncoordinated (Chen et al.,
1994). The dys-1; hlh-1 mutant has been utilized as a way to
strengthen the effects of the dys-1 mutation on muscle degeneration
(Gieseler et al., 2000).
While this sensitized worm may be useful for studying certain
aspects of muscular dystrophy, its relevance to the mechanisms of
muscular dystrophy in humans could be confounded by the
presence of the additional mutation. As a result, any technique
that offers a way to detect muscular defects or decreased function in
muscle in worms with a mutation only in the dys-1 gene arguably
offers a large advantage over these previous assays. We propose that
future work with C. elegans muscular dystrophy models should
follow two main thrusts: screening novel compounds and probing
mechanisms using dys-1(eg33). Our platform is capable of
identifying novel drugs or already approved drugs used for other
purposes that improve muscle function in dys-1(eg33). This could
lead to clinical studies and may also help to unearth unknown
mechanisms associated with dystrophin deficiency. Thus,
answering mechanistic questions in future work is a huge priority.
Conclusion
NemaFlex is a promising platform for screening compounds that
could potentially help to alleviate the loss in muscle strength
associated withmuscular dystrophy. This allows us to studymuscular
dystrophy mechanisms and treatments in the worm without having
to use sensitizing mutations. Subcellular analyses looking at
mitochondrial integrity also enable further assessment of the health
of muscle in dys-1 mutants. The muscular weakness, thrashing
deficiencies, mitochondrial fragmentation, impaired mitochondrial
function and drug response of dys-1(eg33) indicate a clinically
relevant model for future investigations in the worm. Determination
of muscle strength, when paired with other previously established
measures of worm physiology, muscle integrity and overall health,
will offer a more robust method for determining novel compounds for
treating dystrophin-deficient worms.
MATERIALS AND METHODS
Nematode strains and culture
C. elegans strains used in this study were wild-type N2, provided by the
Driscoll Laboratory (Department of Molecular Biology and Biochemistry,
Rutgers University, Piscataway, NJ, USA), and dys-1(eg33) (strain BZ33)
and dys-1(cx18) (strain LS292), provided by the Caenorhabditis Genetics
Center (CGC). Both mutants have nonsense mutations in the dys-1 gene (Oh
and Kim, 2013). We also used four new strains – CC96 [dys-1(eg33) I;
(jls01 (myo-3::GFP, rol-6 (su1006)); unc-54::lacZ V)], CC97 [dys-1(cx18)
I; (jls01 (myo-3::GFP, rol-6 (su1006)); unc-54::lacZ V)], CC90 [dys-
1(cx18) I; ccIs4251 I; him-8(e1489) IV] and CC91 [dys-1(eg33) I; ccIs4251
I; him-8(e1489) IV] – generated for this study to evaluate sarcomere and
mitochondrial network integrity in dys-1(eg33) and dys-1(cx18), along with
PJ727 [ jls01 (myo-3::GFP, rol-6 (su1006)); unc-54::lacZ V] and CB5600
[ccIs4251 (Pmyo-3::Ngfp-lacZ; Pmyo-3::Mtgfp) I; him-8 (e1489) IV], also
provided by the CGC. The PD55 strain was used for OCR experiments.
Animals were maintained at 20°C (unless otherwise noted) on nematode
growth medium (NGM) plates with E. coli OP50 using standard protocol.
Animals for the study were age synchronized by transferring ∼30 gravid
adult nematodes of each strain to the various agar plates (with or without
pharmacological treatments) and then leaving them to lay eggs for ∼3 h.
Adult animals were then removed, and the agar plates with eggs were left in
the 20°C incubator for 3 days. Animal age is given as day of adulthood.
Pharmacological treatments
There were five different groups in this experiment for each of the three
strains studied: no pharmacological intervention (control), melatonin or
prednisone received during development only, and melatonin or prednisone
received during both development and adulthood (Fig. 7A). NGM plates
were prepared normally for the control groups. For the treatments, melatonin
(Sigma-Aldrich) and prednisone (Sigma-Aldrich) were added to the NGM
immediately after autoclaving to final concentrations of 1 mM and
0.37 mM, respectively. The prednisone concentration was chosen as
0.37 mM, as this is a concentration falling within the range of
concentrations previously reported by Gaud et al. (2004) to reduce the
number of damaged muscle cells in the dys-1; hlh-1 model. Similarly, a
concentration of 1 mM of melatonin is within the range of melatonin
concentrations previously reported to affect physiology, specifically the
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number of body bends, in wild-type C. elegans (Tanaka et al., 2007). Thus,
drug concentrations that were selected are values known to fall within the
range of concentrations that affect animal physiology and/or muscle health.
Animals that continued to receive treatment after development,
corresponding to introduction to the microfluidic device on Day 1 of
adulthood, received treatments at concentrations of 0.1 mM and 0.037 mM
for melatonin and prednisone, respectively. Lower concentrations were used
due to the more direct contact with the drug in the microfluidic device
compared with the agar plates.
Animal culture and imaging in microfluidic devices
When animals were ∼72 h posthatching, they were loaded into the
microfluidic devices along with a solution of 100 mg of E. coli ml−1 of
liquid NGM (NGMwithout the agar). For animals continuing to receive the
pharmacological treatment after development, the compound was
introduced into the E. coli solution at the appropriate concentration before
the concentrated bacteria solution was added to the device (Fig. 7B). On
each day for the remainder of the experiment, the devices werewashed using
liquid NGM to remove progeny and debris, and a fresh solution of bacteria
was added to the device (Fig. 7C,D). The arena of pillars and barriers in the
outlet ports allow for the retention of adult animals and the filtering out of
unwanted progeny, as has been previously demonstrated for C. elegans
maintenance in microfluidic devices (Hulme et al., 2010; Wen et al., 2012;
Xian et al., 2013; Wen et al., 2014).
After clearing the devices of progeny and debris, and before adding fresh
E. coli, animals were imaged in the microfluidic chambers (Fig. 7C,D) for
45-s episodes at a rate of five frames per second. A Nikon Eclipse TI-E
microscope with Andor Zyla sCMOS 5.5 camera was used. Any animals
that remained stationary during the first image sequence, although few in
number, were re-imaged until a movie including sufficient worm
locomotion was obtained.
Strength measurements using NemaFlex
Deflections and strength measurements were obtained using standard
NemaFlex processing protocol, which involves automated tracking of the
deflectable pillars (Fig. 7E) (Ghanbari et al., 2012; Johari et al., 2013; Khare
et al., 2015; Qiu et al., 2015). Pillar deflection values extracted during image
processing were converted to forces using Timoshenko beam deflection
Fig. 7. Experimental protocol for testing the efficacy of pharmacological compounds and the microfluidic platform used from the beginning of
adulthood. (A) A summary of the different treatments and associated abbreviation used to describe each treatment. (B) Animals start out on agar for the first
3 days, when development is occurring, and all animals except the control group of each strain receive a pharmacological treatment (pink). On the first day
of adulthood, all animals are transferred to the devices in which they are fed and imaged over the next few days; animals receiving lifelong treatment continue
to receive compounds in the microfluidic device (shown in pink). (C) A view of the 30-chamber microfluidic chip used to house the nematodes from Days 1-5 of
adulthood. The device is bonded on a standard 75×50 mm glass slide. (D) An image of a microfluidic chamber used to house a single worm. The deflectable
pillars enable force measurement. Scale bar: 300 μm. (E) A close-up view of some of the pillars being tracked for deflection via the NemaFlex image-processing
software. Pillars currently in contact with the worm are shown in red; pillars that are deflected in a different frame of the image sequence are shown in blue.
Scale bar: 100 μm.
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theory (Etheridge et al., 2015; Rahman et al., 2018). We then obtained
animal strength from these forces by selecting for the maximal force exerted
in each frame of the acquired image sequence and selecting for the 95th
percentile value (defined as f95) among these maximal forces. The f95 value
for an individual worm is analogous to the maximum voluntary force in
humans, and thus defines a measure of animal muscular strength. Further
details on the methodology and data analysis can be found in Rahman et al.
(2018), and the custom-built software can be obtained by directly contacting
our laboratory. Animal strengths were compared using a two-sample t-test
(MATLAB, R2015b), with each individual animal strength value being
treated as an independent sample. The only animals excluded from the
analysis were those for which the custom-built MATLAB software failed to
process the movie, which can result from too many air bubbles inside the
microfluidic devices or non-uniform illumination. Animal diameters were
measured using ImageJ (https://imagej.nih.gov/ij/).
Thrashing assay
To crosscheck whether worms lacking in strength also exhibit functional
deficiencies in swimming, we used a simple thrashing assay (Gaffney et al.,
2014). There were three different groups for each of the three strains studied
[wild type, dys-1(eg33) and dys-1(cx18)]: no pharmacological intervention
(control) and melatonin (1 mM) or prednisone (0.37 mM) treatment through
the last day of assessment. Animals were age synchronized as described in
the strength assay and maintained on NGM agar plates throughout the
experiment. Animals were manually picked to new plates every other day
during the egg-laying period.
On Days 1, 3 and 5 of adulthood, movement rates of the worms were
recorded using a thrashing assay (also referred to as swim test). Thrashing
assays were carried out by picking a worm into 20 µl M9 buffer on a
microscope slide. The number of bends in 10 s was counted and repeated
five times for each worm for three independent biological replicates.
One body bend was recorded as one rightward body bend and leftward body
bend. For each treatment, movement rates for ten worms were measured.
The differences in movement rates between treatment groups were analyzed
using a two-sample t-test in MATLAB. The same method was utilized for
temperature sensitivity experiments, with the exception that animals were
cultured at 25°C instead of 20°C and significance was assessed using a
two-way ANOVA with Tukey’s multiple comparison test.
Levamisole sensitivity assay
To check for differences in levamisole sensitivity among wild type,
dys-1(cx18) and dys-1(eg33), the groups were exposed to levamisole
hydrochloride (Sigma-Aldrich, 31742) at 100 µM in M9 buffer. Animals
were placed in 2.5 ml levamisole in 30 mm Petri dishes. Starting from
t=0 min, the numbers of paralyzed animals were scored every 10 min until
all wild-type worms were paralyzed. Experiments were performed for
populations of Day 1 adult worms cultured at 20°C or 25°C. For worms
cultured at 20°C, two independent biological replicates were performed,
where n=50 for each experiment (total n=100 per strain). For 25°C, a single
experiment was performed where n=50 per strain.
Sarcomere structure
To determine whether dys-1(cx18) and dys-1(eg33) worms showed defects
in sarcomere structure, the worms were stained with Rhodamine Phalloidin
Stain (Invitrogen, R415). The phalloidin staining procedure was carried out
as described by Gieseler et al. (2000).
In addition to actin staining using phalloidin, crosses were made
using PJ727 [ jls01 (myo-3::GFP, rol-6 (su1006)); unc-54::lacZ V], which
has GFP fusion proteins localized to the contractile apparatus, with
dys-1(eg33) and dys-1(cx18). The resulting crosses were referred to as CC96
[dys-1(eg33) I; (jls01 (myo-3::GFP, rol-6 (su1006)); unc-54::lacZ V)] and
CC97 [dys-1(cx18) I; (jls01 (myo-3::GFP, rol-6 (su1006)); unc-54::lacZ
V)]. Images were taken on Days 0, 1, 2 and 3 of adulthood. All images were
taken at 40× magnification using a Nikon Eclipse 50i microscope.
Mitochondrial strains and imaging
The CB5600 [ccIs4251 (Pmyo-3::Ngfp-lacZ; Pmyo-3::Mtgfp) I; him-8
(e1489) IV] strain, which has GFP fusion proteins localized to muscle
mitochondria and nuclei, was used for this study. Crosses were made
between the CB5600 strain and dys-1(cx18) (LS292 strain) and dys-1(eg33)
(BZ33 strain). The resulting strains were CC90 [dys-1(cx18) I; ccIs4251 I;
him-8(e1489) IV] and CC91 [dys-1(eg33) I; ccIs4251 I; him-8(e1489) IV].
CB5600 was used for the wild-type imaging. On Days 1, 3 and 5 of
adulthood, animals were imaged in 20 µl M9 buffer on a microscope slide
with a cover slip. All images were taken at 40× magnification using a Nikon
Eclipse 50i microscope.
OCR
To investigate DMD-mediated changes in mitochondrial function, OCR
measurements were performed using the Seahorse XFe24 analyzer
(Agilent), in line with previously described methods (Koopman et al.,
2016). On Day 0 of adulthood, wild-type, dys-1(cx18) (LS292 strain) and
dys-1(eg33) (BZ33 strain) animals were washed twice in M9 buffer and
transferred into M9-filled wells (20 worms/well) in replicates of five per
condition (i.e. five wells per strain). To generate stable OCR measurements,
five measurement cycles were performed for basal OCR, nine cycles for
maximal OCR following the addition of FCCP (10 µM final well
concentration) and five cycles for non-mitochondrial OCR, following the
addition of sodium azide (40 nM final well concentration). A follow-up
experiment was conducted to investigate whether prednisone treatment
could rescue DMD-mediated changes in basal OCR. To do this, basal OCR
was measured, as described, in adult (Day 1) wild-type (N2) and
dys-1(eg33) animals both with and without prednisone treatment (20
worms/well, five replicates). Prednisone-treated worms were cultured, as
previously described, on prednisone-treated (0.37 mM) agar. OCR
measurements were normalized to the number of worms per well. To
avoid unstable OCR measurements, the final three, seven and two
measurement cycles were used for the statistical analysis of basal,
maximal and non-mitochondrial OCR, respectively. Differences in OCR
were detected with a one-way ANOVA with Tukey’s multiple comparison
test using GraphPad Prism 6. The α-level of significance was set at P<0.05.
JC-10 and MitoTracker Red staining
To assess mitochondrial membrane potential, two in vivo dyes, JC-10
(Enzo Life Sciences, 52305) and MitoTracker Red CMXRos (Invitrogen,
M7512), were used. Strains used for measuring mitochondrial membrane
potential were wild type (N2), dys-1(cx18) (LS292 strain) and dys-1(eg33)
(BZ33 strain). For prednisone-treated worms, animals were cultured as
previously described on agar containing prednisone at a concentration of
0.37 mM. On the first day of adulthood, 40 worms were picked into 83 µM
JC-10 in freeze-dried OP50 solution (LabTIE) for 4 h before imaging. The
worms stained with MitoTracker Red were imaged on the first day of
adulthood and the protocol by Gaffney et al. (2014) was followed.
Representative images are shown for each strain stained with JC-10 and
MitoTracker Red.
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